Eyegate Pharma (EYEG) Announces Promising Phase 1b/2a Data for EGP-437

December 5, 2016 8:33 AM EST

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) announced promising data from the third stage of its Phase 1b/2a trial assessing lead product candidate, iontophoretic EGP-437, for the treatment of ocular inflammation and pain in post-surgical cataract patients.

Stage three of this multi-center, open-label clinical trial enrolled 30 subjects who have undergone cataract surgery with implantation of a posterior chamber intraocular lens (“IOL”). Patients were divided into three cohorts wherein they received iontophoretic doses of EGP-437 at either 4.5 mA-min or 14.0 mA-min, or a placebo at 14.0 mA-min. Subjects in the EGP-437 14.0 mA-min cohort were administered treatments on day 0 (pre-operative), day 1 and day 4. The other two cohorts were administered treatments on day 0 (post-operative), day 1 and day 4. The potential for an additional treatment on Day 7 at the physician’s discretion was allowed in all three cohorts.

A positive response, determined by a reduction in Anterior Chamber Cell (“ACC”) count, was observed in patients in both of the EGP-437 treatment arms. Those who were administered 4.5 mA-min dosing (3.0 mA for 1.5 minutes) realized the greatest benefit, with 30% and 80% of patients at day 14 and day 28 respectively, achieving complete reduction or an ACC count of zero. The placebo cohort required 80% of patients to be rescued prior to day 14 and only 10% had an ACC count of zero on day 28. Consistent with the first two stages of the trial, the procedure was very well tolerated in all subjects. Patients receiving EGP-437 at both dosing levels experienced reduced pain at all time points, with 70% of patients having a pain score of zero as early as day 1 versus the placebo cohort where only 10% achieved a pain score of zero at day 1.

“We are highly encouraged by the results of this third stage of the Phase 1b/2a study of iontophoretic EGP-437, which reinforce our belief that this product merits further evaluation as a potential treatment for pain and inflammation following cataract surgery,” said Barbara Wirostko M.D., Chief Medical Officer of EyeGate. “We are particularly excited by the outcomes in the 4.5 mA-min treatment arm, which compare favorably to both the placebo arm of this trial and historical data for the current standard of care on reduction in ACC count and improvement in pain score. The data from all stages of this study will form the basis for a randomized, double-masked, placebo controlled trial of iontophoretic EGP-437 in cataract surgery patients, which we expect to initiate in the first half of 2017.”

“EyeGate is developing iontophoretic EGP-437 to potentially eliminate the need for daily corticosteroid eye drops currently used to manage post-surgery pain and inflammation, which could lead to improved outcomes for roughly 3 million patients who undergo cataract surgery in the U.S. each year. The results of this study demonstrate the promise of EGP-437, and we look forward to further demonstrating its ability to improve care for this significant patient population in the upcoming randomized controlled trial,” added Stephen From, Chief Executive Officer of EyeGate.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA